Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study - McArthur, G A; Chapman, P B; Robert, C (Lancet Oncol, 2014)
et al.